These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Overview of lupus nephritis management guidelines and perspective from Asia. Mok CC; Yap DY; Navarra SV; Liu ZH; Zhao MH; Lu L; Takeuchi T; Avihingsanon Y; Yu XQ; Lapid EA; Lugue-Lizardo LR; Sumethkul V; Shen N; Chen SL; Chan TM; Int J Rheum Dis; 2013 Dec; 16(6):625-36. PubMed ID: 24382275 [TBL] [Abstract][Full Text] [Related]
43. Diagnosis and treatment of lupus nephritis flares--an update. Sprangers B; Monahan M; Appel GB Nat Rev Nephrol; 2012 Dec; 8(12):709-17. PubMed ID: 23147758 [TBL] [Abstract][Full Text] [Related]
44. Treating lupus in the kidney: where are we now, and where are we going? Canetta PA; Bomback AS; Radhakrishnan J Discov Med; 2011 Oct; 12(65):341-9. PubMed ID: 22031671 [TBL] [Abstract][Full Text] [Related]
45. Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial. Singh JA; Shah N; Green C BMC Musculoskelet Disord; 2017 Jan; 18(1):53. PubMed ID: 28143529 [TBL] [Abstract][Full Text] [Related]
46. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Corapi KM; Dooley MA; Pendergraft WF Arthritis Res Ther; 2015 Apr; 17(1):110. PubMed ID: 25927414 [TBL] [Abstract][Full Text] [Related]
47. Corticosteroids in Lupus Nephritis and Central Nervous System Lupus. Kamen DL; Zollars ES Rheum Dis Clin North Am; 2016 Feb; 42(1):63-73, viii. PubMed ID: 26611551 [TBL] [Abstract][Full Text] [Related]
48. Major gastrointestinal manifestations in lupus patients in Asia: lupus enteritis, intestinal pseudo-obstruction, and protein-losing gastroenteropathy. Chng HH; Tan BE; Teh CL; Lian TY Lupus; 2010 Oct; 19(12):1404-13. PubMed ID: 20947549 [TBL] [Abstract][Full Text] [Related]
50. [Lupus nephropathy: Insight in new treatments]. Jadot V; Krzesinski JM; Von Frenckell C; Bovy C; Bouquegneau A Nephrol Ther; 2018 Feb; 14(1):1-12. PubMed ID: 29191575 [TBL] [Abstract][Full Text] [Related]
51. Cytomegalovirus infection in Systemic Lupus Erythematosus: report of four cases challenging the management of the disease, and literature review. Sebastiani GD; Iuliano A; Canofari C; Bracci M Lupus; 2019 Mar; 28(3):432-437. PubMed ID: 30674220 [TBL] [Abstract][Full Text] [Related]
52. Current and Emerging Therapies for Lupus Nephritis. Parikh SV; Rovin BH J Am Soc Nephrol; 2016 Oct; 27(10):2929-2939. PubMed ID: 27283496 [TBL] [Abstract][Full Text] [Related]
53. Management of lupus nephropathy. Hebert LA Nephron Clin Pract; 2003 Jan; 93(1):C7-C12. PubMed ID: 12411753 [TBL] [Abstract][Full Text] [Related]
55. Lupus flares in two established end-stage renal disease patients with on-line hemodiafiltration during pregnancy - case series. Althaf MM; Abdelsalam MS; Alfurayh OI Lupus; 2014 Aug; 23(9):945-8. PubMed ID: 24704775 [TBL] [Abstract][Full Text] [Related]
57. Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. Ntatsaki E; Isenberg D Expert Rev Clin Immunol; 2015; 11(7):837-48. PubMed ID: 25973642 [TBL] [Abstract][Full Text] [Related]
58. Lupus Nephritis: Duration of Therapy and Possibility of Withdrawal. Heinlen L; Chakravarty EF Adv Chronic Kidney Dis; 2019 Sep; 26(5):387-392. PubMed ID: 31733723 [TBL] [Abstract][Full Text] [Related]
59. Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Tveita A; Rekvig OP; Zykova SN Arthritis Res Ther; 2008; 10(6):229. PubMed ID: 19090960 [TBL] [Abstract][Full Text] [Related]
60. B-cell signatures for disease flare and response to pre-emptive immunosuppressive therapy in patients with lupus nephritis: abridged secondary publication. Yap YHD; Chan TM; Yung S; Wong S Hong Kong Med J; 2023 Jun; 29 Suppl 3(3):23-26. PubMed ID: 37357587 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]